Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients

Claudia Marchetti, I. Palaia, F. De Felice, A. Musella, C. Donfracesco, L. Vertechy, A. Romito, I. Piacenti, D. Musio, L. Muzii, V. Tombolini, P. Benedetti Panici

Risultato della ricerca: Contributo in rivistaArticolo in rivista


For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.
Lingua originaleEnglish
pagine (da-a)41-46
Numero di pagine6
RivistaCancer Treatment Reviews
Stato di pubblicazionePubblicato - 2016


  • Gynecologic
  • Ovarian cancer
  • Platinum resistant
  • Recurrence
  • Tyrosine-kinases inhibitors


Entra nei temi di ricerca di 'Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients'. Insieme formano una fingerprint unica.

Cita questo